Skip to main content
SpringerLink
Log in

Stereotactic Body Radiotherapy for Oligometastasis

  • Chapter
  • First Online:
Stereotactic Body Radiotherapy

  • 1435 Accesses

Abstract

With tremendous strides in loco regional and systemic therapy many cancer patients present with limited metastatic disease. Just like the precedence of surgical metatstatectomy providing significant numbers of long term survivors, other evolving locoregional therapies can potentially achieve similar results, particularly when surgery is not an option or undesirable. Stereotactic Body Radiotherapy (SBRT) is becoming an increasingly valuable tool in the armamentarium against oligometastatic cancer. Future clinical trials are needed to solidify its role in the setting of systemic, targeted, immune and biological therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kaspers GJL, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica. 2007;92(11):1519–32.

    Article  PubMed  Google Scholar 

  2. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24(25):4143–9.

    Article  CAS  PubMed  Google Scholar 

  3. Saxman SB, Finch D, Gonin R, Einhorn LH. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol. 1998;16(2):702–6.

    CAS  PubMed  Google Scholar 

  4. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004.

    Article  PubMed  Google Scholar 

  5. Hellman S. Karnofsky memorial lecture. Natural history of small breast cancers. J Clin Oncol. 1994;12(10):2229–34.

    CAS  PubMed  Google Scholar 

  6. Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EEW, Vokes EE, et al. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004;25(6):1677–83.

    PubMed  Google Scholar 

  7. McLoughlin JM, Zager JS, Sondak VK, Berk LB. Treatment options for limited or symptomatic metastatic melanoma. Cancer Control [Internet]. 2008 [cited 16 Oct 2013];15(3). Available from: http://moffitt.prod.bridgelinedigital.net/File%20Library/Main%20Nav/Research%20and%20Clinical%20Trials/Cancer%20Control%20Journal/v15n3/239.pdf.

  8. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.

    CAS  PubMed  Google Scholar 

  9. Macdermed DM, Weichselbaum RR, Salama JK. A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol. 2008;98(3):202–6.

    Article  PubMed  Google Scholar 

  10. Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010;40(2):107–11.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg. 1997;113(1):37–49.

    Google Scholar 

  12. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94(7):982–99.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280(17):1485–9.

    Article  CAS  PubMed  Google Scholar 

  14. Miller G, Biernacki P, Kemeny NE, Gonen M, Downey R, Jarnagin WR, et al. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg. 2007;205(2):231–8.

    Article  PubMed  Google Scholar 

  15. Kondo H, Okumura T, Ohde Y, Nakagawa K. Surgical treatment for metastatic malignancies. Pulmonary metastasis: indications and outcomes. Int J Clin Oncol. 2004;10(2):81–5.

    Article  Google Scholar 

  16. Martinez SR, Young SE. A rational surgical approach to the treatment of distant melanoma metastases. Cancer Treat Rev. 2008;34(7):614–20.

    Article  PubMed  Google Scholar 

  17. Allen PJ. The surgical management of metastatic melanoma. Ann Surg Oncol. 2002;9(8):762–70.

    Article  PubMed  Google Scholar 

  18. Timmerman RD, Bizekis CS, Pass HI, Fong Y, Dupuy DE, Dawson LA, et al. Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin. 2009;59(3):145–70.

    Article  PubMed  Google Scholar 

  19. Kavanagh BD, McGarry RC, Timmerman RD. Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin Radiat Oncol. 2006;16(2):77–84.

    Article  PubMed  Google Scholar 

  20. Lax I, Blomgren H, Näslund I, Svanström R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 1994;33(6):677–83.

    Article  CAS  PubMed  Google Scholar 

  21. Shirato H, Shimizu S, Shimizu T, Nishioka T, Miyasaka K. Real-time tumour-tracking radiotherapy. Lancet. 1999;353(9161):1331–2.

    Article  CAS  PubMed  Google Scholar 

  22. Uematsu M, Shioda A, Tahara K, Fukui T, Yamamoto F, Tsumatori G, et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer. 1998;82(6):1062–70.

    Article  CAS  PubMed  Google Scholar 

  23. Koto M, Takai Y, Ogawa Y, Matsushita H, Takeda K, Takahashi C, et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2007;85(3):429–34.

    Article  PubMed  Google Scholar 

  24. Le Q-T, Loo BW, Ho A, Cotrutz C, Koong AC, Wakelee H, et al. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol. 2006;1(8):802–9.

    Article  PubMed  Google Scholar 

  25. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833–9.

    Article  PubMed  Google Scholar 

  26. Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75(3):677–82.

    Article  PubMed  Google Scholar 

  27. McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;63(4):1010–5.

    Article  PubMed  Google Scholar 

  28. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63(5):1427–31.

    Article  PubMed  Google Scholar 

  29. Hara R, Itami J, Kondo T, Aruga T, Abe Y, Ito M, et al. Stereotactic single high dose irradiation of lung tumors under respiratory gating. Radiother Oncol. 2002;63(2):159–63.

    Article  PubMed  Google Scholar 

  30. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101(7):1623–31.

    Article  PubMed  Google Scholar 

  31. Okunieff P, Petersen AL, Philip A, Milano MT, Katz AW, Boros L, et al. Stereotactic body radiation therapy (SBRT) for lung metastases. Acta Oncol. 2006;45(7):808–17.

    Article  PubMed  Google Scholar 

  32. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009;27(10):1579–84.

    Article  PubMed  Google Scholar 

  33. Meijneke TR, Petit SF, Wentzler D, Hoogeman M, Nuyttens JJ. Reirradiation and stereotactic radiotherapy for tumors in the lung: dose summation and toxicity. Radiother Oncol. 2013;107(3):423–7.

    Article  PubMed  Google Scholar 

  34. Norihisa Y, Nagata Y, Takayama K, Matsuo Y, Sakamoto T, Sakamoto M, et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys. 2008;72(2):398–403.

    Article  PubMed  Google Scholar 

  35. Guckenberger M, Heilman K, Wulf J, Mueller G, Beckmann G, Flentje M. Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. Radiother Oncol. 2007;85(3):435–42.

    Article  PubMed  Google Scholar 

  36. Song DY, Benedict SH, Cardinale RM, Chung TD, Chang MG, Schmidt-Ullrich RK. Stereotactic body radiation therapy of lung tumors: preliminary experience using normal tissue complication probability-based dose limits. Am J Clin Oncol. 2005;28(6):591–6.

    Article  PubMed  Google Scholar 

  37. Blomgren H, Lax I, Näslund I, Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Acta Oncol. 1995;34(6):861–70.

    Article  CAS  PubMed  Google Scholar 

  38. Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol. 2001;19(1):164–70.

    CAS  PubMed  Google Scholar 

  39. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005;62(5):1371–8.

    Article  PubMed  Google Scholar 

  40. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572–8.

    Article  PubMed  Google Scholar 

  41. Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27(10):1585–91.

    Article  PubMed  Google Scholar 

  42. Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys. 2007;67(3):793–8.

    Article  PubMed  Google Scholar 

  43. Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011;117(17):4060–9.

    Article  PubMed  Google Scholar 

  44. Biasco G, Derenzini E, Grazi G, Ercolani G, Ravaioli M, Pantaleo MA, et al. Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. Cancer Treat Rev. 2006;32(3):214–28.

    Article  CAS  PubMed  Google Scholar 

  45. Almaghrabi MY, Supiot S, Paris F, Mahé M-A, Rio E. Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review. Radiat Oncol [Internet]. 2012 [cited 16 Oct 2013];7(1). Available from: http://www.biomedcentral.com/content/pdf/1748–717X-7–126.pdf.

  46. Inoue T, Katoh N, Aoyama H, Onimaru R, Taguchi H, Onodera S, et al. Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions. Jpn J Clin Oncol. 2010;40(8):788–94.

    Article  PubMed  Google Scholar 

  47. Milano MT, Zhang H, Metcalfe SK, Muhs AG, Okunieff P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009;115(3):601–8.

    Article  PubMed  Google Scholar 

  48. Weichselbaum R. Phase I, dose escalation of hypofractionated radiation therapy for patients with oligometastasis. Int J Radiat Oncol Biol Phys. 2006;66:S523.

    Article  Google Scholar 

  49. McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B. Observation of a dose–control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009;73(1):112–8.

    Article  PubMed  Google Scholar 

  50. Carey Sampson M, Katz A, Constine LS. Stereotactic body radiation therapy for extracranial oligometastases: does the sword have a double edge? Semin Radiat Oncol. 2006;16(2):67–76.

    Article  PubMed  Google Scholar 

  51. Onimaru R, Shirato H, Shimizu S, Kitamura K, Xu B, Fukumoto S, et al. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys. 2003;56(1):126–35.

    Article  PubMed  Google Scholar 

  52. Wulf J, Hädinger U, Oppitz U, Thiele W, Ness-Dourdoumas R, Flentje M. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol. 2001;177(12):645–55.

    Article  CAS  PubMed  Google Scholar 

  53. Yoon SM, Choi EK, Lee S-W, Yi BY, Ahn SD, Shin SS, et al. Clinical results of stereotactic body frame based fractionated radiation therapy for primary or metastatic thoracic tumors. Acta Oncol. 2006;45(8):1108–14.

    Article  PubMed  Google Scholar 

  54. Brown WT, Wu X, Fowler JF, García S, Fayad F, Amendola BE, et al. Lung metastases treated by CyberKnife image-guided robotic stereotactic radiosurgery at 41 months. South Med J. 2008;101(4):376–82.

    Article  PubMed  Google Scholar 

  55. Ricardi U, Filippi AR, Guarneri A, Ragona R, Mantovani C, Giglioli F, et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer. 2012;75(1):77–81.

    Article  PubMed  Google Scholar 

  56. Blomgren H, Lax I, Göranson H, Kraepelien T, Nilsson B, Näslund I, et al. Radiosurgery for tumors in the body: clinical experience using a new method. J Radiosurgery. 1998;1(1):63–74.

    Article  Google Scholar 

  57. Hoyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45(7):823–30.

    Article  PubMed  Google Scholar 

  58. Kavanagh BD, Schefter TE, Cardenes HR, Stieber VW, Raben D, Timmerman RD, et al. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 2006;45(7):848–55.

    Article  PubMed  Google Scholar 

  59. Méndez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJM, Nowak PCJM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study. Acta Oncol. 2006;45(7):831–7.

    Article  PubMed  Google Scholar 

  60. Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010;78(2):486–93.

    Article  PubMed  Google Scholar 

  61. Rule W, Timmerman R, Tong L, Abdulrahman R, Meyer J, Boike T, et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol. 2011;18(4):1081–7.

    Article  PubMed  Google Scholar 

  62. Choi CW, Cho CK, Yoo SY, Kim MS, Yang KM, Yoo HJ, et al. Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. Int J Radiat Oncol Biol Phys. 2009;74(1):147–53.

    Article  PubMed  Google Scholar 

  63. Jereczek-Fossa BA, Piperno G, Ronchi S, Catalano G, Fodor C, Cambria R, et al. Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer. Am J Clin Oncol. 2014;37(3):227–33.

    Google Scholar 

  64. Kim M-S, Yoo SY, Cho CK, Yoo HJ, Yang KM, Kang JK, et al. Stereotactic body radiotherapy for isolated para-aortic lymph node recurrence after curative resection in gastric cancer. J Korean Med Sci. 2009;24(3):488–92.

    Article  PubMed Central  PubMed  Google Scholar 

  65. Kim M-S, Cho CK, Yang KM, Lee DH, Moon SM, Shin YJ. Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence from colorectal cancer. World J Gastroenterol. 2009;15(48):6091–5.

    Article  PubMed Central  PubMed  Google Scholar 

  66. Bignardi M, Navarria P, Mancosu P, Cozzi L, Fogliata A, Tozzi A, et al. Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases. Int J Radiat Oncol Biol Phys. 2011;81(3):831–8.

    Article  PubMed  Google Scholar 

  67. Casamassima F, Masi L, Menichelli C, Bonucci I, Casamassima E, Lazzeri M, et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori. 2011;97(1):49–55.

    CAS  PubMed  Google Scholar 

  68. Casamassima F, Livi L, Masciullo S, Menichelli C, Masi L, Meattini I, et al. Stereotactic radiotherapy for adrenal gland metastases: University of Florence experience. Int J Radiat Oncol Biol Phys. 2012;82(2):919–23.

    Article  PubMed  Google Scholar 

  69. Chawla S, Chen Y, Katz AW, Muhs AG, Philip A, Okunieff P, et al. Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys. 2009;75(1):71–5.

    Article  PubMed  Google Scholar 

  70. Oshiro Y, Takeda Y, Hirano S, Ito H, Aruga T. Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer. Am J Clin Oncol. 2011;34(3):249–53.

    Article  PubMed  Google Scholar 

  71. Holy R, Piroth M, Pinkawa M, Eble MJ. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol. 2011;187(4):245–51.

    Article  PubMed  Google Scholar 

  72. Torok J, Wegner RE, Burton SA, Heron DE. Stereotactic body radiation therapy for adrenal metastases: a retrospective review of a noninvasive therapeutic strategy. Future Oncol. 2011;7(1):145–51.

    Article  CAS  PubMed  Google Scholar 

  73. Scorsetti M, Alongi F, Filippi AR, Pentimalli S, Navarria P, Clerici E, et al. Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. Acta Oncol. 2012;51(5):618–23.

    Article  PubMed  Google Scholar 

  74. Salama JK, Saba N, Quon H, Garg MK, Lawson J, McDonald MW, et al. ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck. Oral Oncol. 2011;47(7):554–9.

    Article  PubMed  Google Scholar 

  75. Kang J-K, Kim M-S, Kim JH, Yoo SY, Cho CK, Yang KM, et al. Oligometastases confined one organ from colorectal cancer treated by SBRT. Clin Exp Metastasis. 2010;27(4):273–8.

    Article  PubMed  Google Scholar 

  76. Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011;6:34.

    Article  PubMed Central  PubMed  Google Scholar 

  77. Bae SH, Kim M-S, Cho CK, Kang J-K, Kang HJ, Kim YH, et al. High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. J Surg Oncol. 2012;106(2):138–43.

    Article  PubMed  Google Scholar 

  78. Wersäll PJ, Blomgren H, Lax I, Kälkner K-M, Linder C, Lundell G, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol. 2005;77(1):88–95.

    Article  PubMed  Google Scholar 

  79. Svedman C, Sandström P, Pisa P, Blomgren H, Lax I, Kälkner K-M, et al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 2006;45(7):870–5.

    Article  PubMed  Google Scholar 

  80. Nuyttens JJ, Prevost J-B, Van der Voort van Zijp NC, Hoogeman M, Levendag PC. Curative stereotactic robotic radiotherapy treatment for extracranial, extrapulmonary, extrahepatic, and extraspinal tumors: technique, early results, and toxicity. Technol Cancer Res Treat. 2007;6(6):605–10.

    Article  CAS  PubMed  Google Scholar 

  81. Greco C, Zelefsky MJ, Lovelock M, Fuks Z, Hunt M, Rosenzweig K, et al. Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int J Radiat Oncol Biol Phys. 2011;79(4):1151–7.

    Article  PubMed  Google Scholar 

  82. Chetty IJ, Devpura S, Liu D, Chen D, Li H, Wen NW, et al. Correlation of dose computed using different algorithms with local control following stereotactic ablative radiotherapy (SABR)-based treatment of non-small-cell lung cancer. Radiother Oncol. 2013;109(3):498–504.

    Article  PubMed  Google Scholar 

  83. Altunbas C, Kavanagh B, Dzingle W, Stuhr K, Gaspar L, Miften M. Dosimetric errors during treatment of centrally located lung tumors with stereotactic body radiation therapy: Monte Carlo evaluation of tissue inhomogeneity corrections. Med Dosim. 2013;38(4):436–41.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Istanbul Medical Faculty, Istanbul, Turkey

    Nergiz R. Dagoglu MD

  2. Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    Anand Mahadevan MD, FRCS, FRCR

Authors
  1. Nergiz R. Dagoglu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anand Mahadevan MD, FRCS, FRCR
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anand Mahadevan MD, FRCS, FRCR .

Editor information

Editors and Affiliations

  1. Guy's Hospital, London, United Kingdom

    Andrew Gaya

  2. Dept. Radiation Oncology, Harvard Medical School Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

    Anand Mahadevan

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Dagoglu, N.R., Mahadevan, A. (2015). Stereotactic Body Radiotherapy for Oligometastasis. In: Gaya, A., Mahadevan, A. (eds) Stereotactic Body Radiotherapy. Springer, London. https://doi.org/10.1007/978-0-85729-597-2_13

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-597-2_13

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-596-5

  • Online ISBN: 978-0-85729-597-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation